Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
Gynecologic Oncology
|
February 14, 2026
Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts
Luca Palmieri, Stefania Bellone, Cem Demirkiran, et al.
Gynecologic Oncology
|
May 4, 2024
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas
Cem Demirkiran, Michelle Greenman, Stefania Bellone, et al.
Gynecologic Oncology
|
March 16, 2024
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer
Blair McNamara, Cem Demirkiran, Tobias Max Philipp Hartwich, et al.
International Journal of Molecular Sciences
|
September 27, 2025
Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor
Cem Demirkiran, Stefania Bellone, Victoria M Ettorre, et al.
Gynecologic Oncology
|
January 27, 2023
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo
Chanhee Han, Blair McNamara, Stefania Bellone, et al.
Gynecologic Oncology
|
January 7, 2023
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression
Dennis Mauricio, Stefania Bellone, Levent Mutlu, et al.
Clinical & Experimental Metastasis
|
June 22, 2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Levent Mutlu, Blair McNamara, Stefania Bellone, et al.
Gynecologic Oncology
|
November 28, 2022
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma
Justin Harold, Stefania Bellone, Diego D Manavella, et al.
Gynecologic Oncology
|
March 11, 2023
Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma"
Justin Harold, Stefania Bellone, Diego D Manavell, et al.
Molecular Cancer Therapeutics
|
September 7, 2023
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma
Levent Mutlu, Diego D Manavella, Stefania Bellone, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
Gynecologic Oncology
|
February 14, 2026
Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts
Luca Palmieri, Stefania Bellone, Cem Demirkiran, et al.
Gynecologic Oncology
|
May 4, 2024
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas
Cem Demirkiran, Michelle Greenman, Stefania Bellone, et al.
Gynecologic Oncology
|
March 16, 2024
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer
Blair McNamara, Cem Demirkiran, Tobias Max Philipp Hartwich, et al.
International Journal of Molecular Sciences
|
September 27, 2025
Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor
Cem Demirkiran, Stefania Bellone, Victoria M Ettorre, et al.
Gynecologic Oncology
|
January 27, 2023
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo
Chanhee Han, Blair McNamara, Stefania Bellone, et al.
Gynecologic Oncology
|
January 7, 2023
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression
Dennis Mauricio, Stefania Bellone, Levent Mutlu, et al.
Clinical & Experimental Metastasis
|
June 22, 2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Levent Mutlu, Blair McNamara, Stefania Bellone, et al.
Gynecologic Oncology
|
November 28, 2022
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma
Justin Harold, Stefania Bellone, Diego D Manavella, et al.
Gynecologic Oncology
|
March 11, 2023
Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma"
Justin Harold, Stefania Bellone, Diego D Manavell, et al.
Molecular Cancer Therapeutics
|
September 7, 2023
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma
Levent Mutlu, Diego D Manavella, Stefania Bellone, et al.
Page
of 4